Search
Now showing items 11-15 of 15
Anticomplementary activity of equine whole IgG antivenoms: comparison of three fractionation protocols
(2005-01)
Early adverse reactions occur in a number of patients treated with heterologous antivenoms and have been associated with anticomplementary activity (ACA). In order to reduce the ACA of equine whole IgG antivenoms produced ...
Antivenoms for Snakebite Envenomings
(2011-10)
Animal-derived antivenoms constitute the mainstay in the therapy of snakebite envenoming. Antivenoms are manufactured by immunizing animals, usually horses, with venoms from a single or several medically-relevant snake ...
Preclinical evaluation of the efficacy of antivenoms for snakebite envenoming: State-of-the-art and challenges ahead
(2017-05)
Animal-derived antivenoms constitute the mainstay in the therapy of snakebite envenoming. The efficacy of antivenoms to neutralize toxicity of medically-relevant snake venoms has to be demonstrated through meticulous ...
Proteomic and toxinological characterization of the venom of the South African Ringhals cobra Hemachatus haemachatus
(2018-06)
The protein composition and toxinological profile of the venom of the African spitting elapid Hemachatus haemachatus
(Ringhals) were characterized by bottom-up proteomics and functional in vitro and in vivo assays.
Venom ...
Human heterophilic antibodies against equine immunoglobulins: assessment of their role in the early adverse reactions to antivenom administration
(2008)
The presence of human heterophilic antibodies against horse immunoglobulins
(HHA-HI) was determined by ELISA in sera from healthy volunteers and from patients who
received equine antivenom for therapy of snake bite ...